MetLife Investment Advisors LLC Cuts Position in Gilead Sciences, Inc. (NASDAQ:GILD)

MetLife Investment Advisors LLC cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.0% in the 1st quarter, HoldingsChannel reports. The fund owned 362,580 shares of the biopharmaceutical company’s stock after selling 7,373 shares during the quarter. MetLife Investment Advisors LLC’s holdings in Gilead Sciences were worth $23,571,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Lenox Wealth Management Inc. raised its stake in shares of Gilead Sciences by 1.8% during the first quarter. Lenox Wealth Management Inc. now owns 9,059 shares of the biopharmaceutical company’s stock valued at $589,000 after acquiring an additional 156 shares during the last quarter. Vectors Research Management LLC raised its stake in shares of Gilead Sciences by 6.3% during the fourth quarter. Vectors Research Management LLC now owns 2,651 shares of the biopharmaceutical company’s stock valued at $166,000 after acquiring an additional 157 shares during the last quarter. Creative Financial Designs Inc. ADV raised its stake in shares of Gilead Sciences by 55.9% during the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 165 shares during the last quarter. Rathbone Brothers plc raised its stake in shares of Gilead Sciences by 3.1% during the first quarter. Rathbone Brothers plc now owns 5,547 shares of the biopharmaceutical company’s stock valued at $361,000 after acquiring an additional 167 shares during the last quarter. Finally, B. Riley Wealth Management Inc. raised its stake in shares of Gilead Sciences by 2.9% during the first quarter. B. Riley Wealth Management Inc. now owns 6,576 shares of the biopharmaceutical company’s stock valued at $428,000 after acquiring an additional 184 shares during the last quarter. Institutional investors own 78.68% of the company’s stock.

Several equities analysts have recently commented on GILD shares. Mizuho reaffirmed a “buy” rating and set a $88.00 price objective on shares of Gilead Sciences in a research note on Tuesday, February 26th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Thursday, March 7th. Piper Jaffray Companies set a $75.00 price objective on shares of Gilead Sciences and gave the company a “hold” rating in a research note on Thursday, March 7th. BMO Capital Markets started coverage on shares of Gilead Sciences in a research note on Thursday, March 14th. They set an “outperform” rating and a $78.00 price objective for the company. Finally, Oppenheimer set a $85.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Tuesday, March 19th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $79.54.

Shares of NASDAQ GILD opened at $66.36 on Monday. Gilead Sciences, Inc. has a 1 year low of $60.32 and a 1 year high of $79.61. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.53 and a current ratio of 3.62. The stock has a market cap of $84.60 billion, a P/E ratio of 10.79, a P/E/G ratio of 0.64 and a beta of 1.09.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.53 by $0.23. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The company had revenue of $5.28 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter in the previous year, the company earned $1.48 earnings per share. Gilead Sciences’s quarterly revenue was up 3.8% on a year-over-year basis. As a group, equities analysts predict that Gilead Sciences, Inc. will post 6.6 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.80%. The ex-dividend date is Thursday, June 13th. Gilead Sciences’s dividend payout ratio is currently 40.98%.

In other Gilead Sciences news, Director Richard James Whitley sold 9,534 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $65.48, for a total value of $624,286.32. Following the sale, the director now owns 34,669 shares in the company, valued at $2,270,126.12. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director John Francis Cogan sold 2,700 shares of the company’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $65.07, for a total transaction of $175,689.00. Following the completion of the sale, the director now owns 57,560 shares in the company, valued at approximately $3,745,429.20. The disclosure for this sale can be found here. Insiders have sold 28,602 shares of company stock worth $1,863,445 in the last quarter. 0.20% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This news story was reported by Enterprise Leader and is owned by of Enterprise Leader. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://theenterpriseleader.com/2019/06/17/metlife-investment-advisors-llc-cuts-position-in-gilead-sciences-inc-nasdaqgild.html.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: What is a short straddle?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.